2018 saw the first year where the number of drugs entering development came from emerging pharma compared to large pharma. As these companies rely heavily on outsourcing, they turn to their providers not only for resource needs, but also for expertise to guide them through the minefield of early development. As bio-enhancement of NCEs is often a critical driver for successful transition through preclinical studies, it is essential that the CRO/CDMO selected has the right knowledge to support this stage of work. This presentation will focus on the following key aspects:
- The concept of rapid early development of poorly soluble drugs
- Scale-up considerations for bioavailability enhancing technologies
- A consultant perspective on selecting CDMO for the right partnership for drug development
- How a CDMO can offer advantages in terms of scalability, speed to market, access to technical expertise and potential cost efficiencies?